Table 1.
The survival rates of CRS plus IPHC in patients with PC of different malignancies
| Authors | Pts | Year | Type of | Tumor type | Drugs, temperature | Median |
Survival rate (%) |
||||
| n | study | & duration | follow-up time | 1 yr | 2 yr | 3 yr | 4 yr | 5 yr | |||
| Pilati et al[90] | 34 | 2003 | Phase II | Colon ca | MMC 26.2 mg (20.1-31.6 mg) CDDP 193.7 mg (170-241.1 mg), 41.5°C (41.2°C-42.1°C), 90 min | 14.5 mo (6-34 mo) | 68 | 31 | - | - | - |
| Glehen et al[81] | 56 | 2003 | Phase II | CRC, OC, GC, peritoneal Mesothelioma, Pseudomyxoma peritonei, and others | MMC 0.7 mg/kg (max dose 60 mg), CDDP 1 mg/kg (max dose 80 mg), 46°C-48°C, 90 min | 544.4 d (133-1680 d) | - | R0: 79.0; R2: 44.7 | - | - | - |
| Verwaal et al[67] | 54 | 2003 | Phase III | CRC | MMC 70 mg, 41°C-42°C, 90 min | 21.6 mo | 67 | 44 | - | - | - |
| Witkamp et al[60] | 29 | 2001 | PhaseI/II | CRC | MMC 35 mg/m2, 40°C-41°C, 90 min | 38 mo (26-52 mo) | 82 | 45 | 23 | - | - |
| Shen et al[84] | 77 | 2004 | Phase II | CRC | MMC 40 mg, 40.5°C, 120 min | 15 m | 56 | - | 25 | - | 17 |
| Elias et al[91] | 24 | 2004 | Phase II | CRC | LOHP 460 mg/m2 in 2 L/m2, 43°C, 30 min | 27.4 mo (18.3-49.6 mo) | 83 | 74 | 65 | - | - |
| Yonemura et al[92] | 107 | 2005 | - | GC | MMC 30 mg, CDDP 300 mg, etoposide 150 mg, 42°C-43°C | 46 mo | - | - | - | - | 6.7 all pts; 27 R0 pts |
| Yonemura et al[93] | 48 | 2001 | Randomized study | T2-T4 GC | MMC 30 mg, CDDP 300 mg, 42°C-43°C, 60 min | 5.5 yr (2.4-10.8 yr) | - | - | - | - | 61 |
| Elias et al[94] | 30 | 2006 | Phase II | CRC | LOHP 460 mg/m2 in 2 L/m2 of iso-osmotic 5% dextrose, 43°C, 30 min | 55 mo (24-80 mo) | 97 | 73 | 53 | 49 | - |
| Yan et al[75] | 30 | 2006 | - | CRC | - | 12 mo | 72 | 64 | - | - | - |
| Glehen et al[78] | 53 | 2004 | Phase II | CRC | MMC 40-60 mg, 46°C-48°C, 90 min | 60 mo | 55 | 32 | - | - | 11 |
| Helm et al[95] | 18 | 2007 | Retrospective review | Recurrent OC | CDDP 100 mg/m2 or MMC 30-40 mg, 41°C-43°C, 90 min | 16.2 mo (6-33 mo) | - | 60 | - | - | - |
| Deraco et al[96] | 33 | 2004 | phase II | Pseudomyxoma peritonei | CDDP 25 mg/m2 per L plus MMC 3.3 mg/m2 per L, 60 min, 42.5°C | 28.6 mo (0.4-72 mo) | - | - | - | - | 97 |
| Cavaliere et al[97] | 69 | 2003 | Phase II | CRC | MMC | - | - | - | 27 | - | - |
| Glehen et al[66] | 506 | 2004 | Phase II | CRC | MMC/LOHP, 40°C-43°C, 30-90 min | 53 mo | 72 | - | 39 | - | 19 |
| Verwaal et al[98] | 117 | 2005 | Phase II | CRC | MMC 35 mg/m2, 40°C-41°C, 90 min | 46 mo | 75 | - | 28 | - | 19 |
| Sugarbaker et al[72] | 70 | 2006 | Phase II | CRC | MMC | 47 mo | 88 | - | 44 | - | 32 |
| Helm et al[99] | 5 | 2007 | Retrospective review | Recurrent endometrial ca | CDDP 100 mg/m2, 41°C-43°C, 90 min | 36 mo | 80 | 80 | 80 | 80 | - |
| Zanon et al[100] | 25 | 2006 | Phase II | CRC | MMC 15 mg/m2, 42°C, 60 min | 36 mo | 64 | 40 | - | - | - |
| Piso et al[101] | |||||||||||
| 19 | 2004 | - | OC | CDDP 75 mg/m2, or mitoxantrone 15 mg/m2, 41.5°C, 90 min | - | - | - | - | - | 15 | |
| Roviello et al[102] | 59 | 2006 | - | OC, CRC, GC, Pseudomyxoma, Mesothelioma | MMC 25 mg/m2, CDDP 100 mg/m2. (LOHP 460 mg/m2 in 4 pts with colorectal PC), 41°C-43°C, 60 min | 25 ± 21 mo | - | - | - | - | 50.8 |
GC: Gastric cancer; CRC: Colorectal cancer; OC: Ovarian cancer; MMC: Mitomycin C; CDDP: Cisplatin; LOHP: Oxaliplatin.